A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ARGX-109 Administered Subcutaneously in Healthy Adult Participants
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Gerilimzumab (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors argenx
- 03 Feb 2025 New trial record